SCHEMBL24666100

SCHEMBL24666100

Cc1cc(C(F)F)n(CC(C)C)n1

nearest known ligand 0.44

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.44
APAF1 O14727 1/20 0.44
POLB P06746 1/20 0.44
KMT2A Q03164 2/20 0.37
MEN1 O00255 1/20 0.37
KDM4E B2RXH2 2/20 0.36
ALDH1A1 P00352 2/20 0.36
GLA P06280 1/20 0.36
GLS O94925 1/20 0.35
CYP1A2 P05177 1/20 0.34
CYP3A4 P08684 1/20 0.34
CYP2C9 P11712 1/20 0.34
CYP2C19 P33261 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.33
GAA P10253 2/20 0.33
HPGD P15428 1/20 0.32
AURKA O14965 1/20 0.32
AURKB Q96GD4 1/20 0.32
TP53 P04637 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15481075 0.85 LMNA (0.46) LMNAAPAF1POLBKMT2AKDM4E
SCHEMBL21471125 0.83 ALDH1A1 (0.40) LMNAAPAF1POLBKMT2AMEN1
SCHEMBL24665886 0.81 GAA (0.45) LMNAAPAF1POLBKMT2AMEN1
SCHEMBL22667163 0.78 LMNA (0.44) LMNAAPAF1POLBKMT2AKDM4E
SCHEMBL2356858 0.77 LMNA (0.44) LMNAAPAF1POLBKMT2AKDM4E
SCHEMBL2608929 0.76 LMNA (0.62) LMNAAPAF1POLBKMT2AKDM4E
SCHEMBL22681214 0.75 ALDH1A1 (0.38) LMNAPOLBKMT2AKDM4EALDH1A1
SCHEMBL15292515 0.74 LMNA (0.49) LMNAAPAF1POLBKMT2AMEN1
SCHEMBL23398583 0.73 LMNA (0.46) LMNAAPAF1POLBKMT2AMEN1
SCHEMBL11128959 0.73 POLB (0.50) LMNAAPAF1POLBKMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024059665-A1 DIMERIC COMPOUNDS AS INHIBITORS OF GLYCOGEN SYNTHASE 1 (GYS1) AND METHODS OF USE THEREOF MAZE THERAPEUTICS, INC. (US) 2024-03-21 WO disclosed
US-11814367-B2 Inhibitors of glycogen synthase 1 (GYS1) and methods of use thereof MAZE THERAPEUTICS, INC. (US) 2023-11-14 US disclosed
US-11814367-B2 Inhibitors of glycogen synthase 1 (GYS1) and methods of use thereof MAZE THERAPEUTICS, INC. (US) 2023-11-14 US disclosed
WO-2022198196-A1 INHIBITORS OF GLYCOGEN SYNTHASE 1 (GYS1) AND METHODS OF USE THEREOF MAZE THERAPEUTICS, INC. (US) 2022-09-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11814367-B2 Inhibitors of glycogen synthase 1 (GYS1) and methods of use thereof GYS2, GYS1, PYGL LMNA 393/4885APAF1 4768/4885POLB 2862/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.